The FDA approved the new therapy Orcrevus and the multiple sclerosis community is feeling hopeful.
There are various types of multiple sclerosis and most MS patients start with a diagnosis of Relapsing Remitting or RRMS. Therefore, much of the disease modifying treatments and studies are geared towards this type of MS. However, the research is always changing and there are new disease modifying treatments and studies.
The latest FDA approved therapy is Orcrevus also known as Ocrelizumab. What is promising about this medication is that it is geared to treat progressive forms of MS. Orcrevus will be the first of its kind for PPMS patients that have had no therapies specifically targeted to them.
Orcrevus aims for B-cells in the system in efforts to control inflammation which is determined to be most cause of MS flares or attacks and is administered intravenously twice yearly. Although, Orcrevus is being hailed for its treatment of progressive MS, it will be available to RRMS patients as well.
Roche developed Orcrevus and is the company’s first MS drug. With this addition of Orcrevus to the roster of disease modifying therapies, patients are one step closer to healing and possibly halting multiple sclerosis.
Are you hopeful about Orcrevus?